THOMSON

452

Prous Science Drug Data Report

FILE DESCRIPTION

The **Prous Science Drug Data Report** database provides continuously updated information on more than 65,000 bioactive compounds reported in the print journal *Prous Science Drug Data Report* since June 1988. Compounds are "followed" from the patent application stage through research and development phases to approval, marketing, and postmarketing periods. Approximately 10,000 records are added to the database each year. The Prous Science Drug Data Report database is a valuable source of up-to-date information for professionals in research, development, management, marketing, licensing, and information sciences within the pharmaceutical industry and for all those interested in this industry activities.

SUBJECT COVERAGE

Fields in the Prous Science Drug Data Report database include:

- molecular formula
- chemical names
- chemical structure
- company code names
- generic names and synonyms
- brand names
- industrial or other sources
- licensees
- activity index numbers and activity classes
- development phase
- CAS registry numbers
- physical data
- related compounds
- relevant patent information (titles, inventors, applicants/assignees, patent, and priority numbers)
- literature references (title, author, source), and concise text describing the compound's biological activity.

The entries in the Prous Science Drug Data Report database are included from information compiled from published and unpublished sources: current literature references (as of June 1, 1995, more than 100,000 are included in the database); patent references (more than 20,000) from 11 different sources; international congresses and symposia (more than 160 anually); scientific contributions; and company communications (from more than 850 companies).

TIPS

USE FILE 452

to monitor drugs in the pipeline from preclinical, clinical (phase I, phase II, or phase III) as well as launch, registered, etc., all indexed by development status (ST=).

USE THERAPEUTIC CODES

to choose therapeutic class

EXPAND TC=10000

or

SELECT ANTICONVULSANT/TC

USE FORMAT 13

to display full record except text & literature references with image.

USE FORMAT 19

to display full record with image(s).

DIALOG FILE DATA

Inclusive Dates: June 1, 1988 to the present

Update Frequency:

Monthly (Approximately 1,000 records)

File Size: More than 118,000 records as of April 2000

CONTACT

Prous Science Drug Data Report is provided by Prous Science Publishers. Questions concerning file content should be directed to:

Prous Science
P.O. Box 540
Barcelona 08080
Spain
Phone: +34 93 459 2220
Fax: +34 93 458 1535
E-Mail: service@prous.es

Prous Science Drug Data Report

	DIALOG(R)File 452:Prous Science Drug Data Report
	(c) 2000 J.R. Prous S.A. All rts. reserv.
	00149658
AA=	ENTRY NUMBER: 149658
	COMPOUND TYPE: Preferred
/SY, SY=,/NA,NA=	DRUG NAME: 256U87
	BW-256U
	ValACV
/NA,NA=	GENERIC NAME Valaciclovir (recommended INN)
	Valacyclovir (USAN)
/TN,TN=	BRAND NAME: Valtrex (Wellcome, GB, EI)
/CN,CN=	CHEM NAME: L-Valine 2-(2-amino-6-hydroxy-9H-purin-9-ylmethoxy) ethyl ester
	L-Valine 2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-ylmethoxy)ethyl ester
	L-Valine 2-(guanin-9-ylmethoxy)ethyl ester
MF=	FORMULA: C13H20N6O4
RN=	CAS REG. NO.: 124832-26-4
	124832-27-5 (monoHCl salt)
ST=	DEVEL. PHASE: Launched (1995)
/LO, LO=	ORIGINATOR: Wellcome
/LI, LI=	LICENSEE: Hoechst
	Theraplix
RE=	RELATED ENTRY: 151566 (secondary)
/TX	ACTION: Antiviral agent, ester of the antiherpetic compound acyclovir, with better water solubility and gastrointestinal absorption after oral administration than acyclovir, without substantial decline of the antiviral activity in vitro. In rats, urinary recovery as acyclovir was 63 % of the dose for the title compound and 15 % for acyclovir. Another specifically claimed amino acid ester of the known purine nucleoside is: 151566. (Drug Data Report, Vol. 11, No. 7, p. 592, 1989)
	ACTION: Acyclovir prodrug, ester with L-valine that was found to berapidly converted to the parent compound in studies in rats and primates; due to good results in these studies, it was advanced to clinical testing in man. In single-dose studies in healthy volunteers , it gave peak acyclovir values of 0.8 +/- 0.1 and 5.6 +/- 2.4 mcg/ml at 24 h after administration of 100 or 1000 mg, respectively. Mean t1/2 at all doses was approx. 28 h. After multiple doses in volunteers (250,500 or 1000 mg four times daily for 11 days), pharmacokinetic parameters were similar to those after single dosing. Due to the compound'senhanced delivery of acyclovir and its favorable pharmacokinetic profile, it has been moved to phase II studies. (Drug Data Report, Vol. 13, No. 11, p. 998, 1991)
	PREV. PUB. IN: Drugs of the Future, Vol. 18, No. 7, p. 619, 1993
	PATENTS:
/TI	THERAPEUTIC NUCLEOSIDES
AU=	AUTHOR(s): Beauchamp, L.M., Krenitsky, T.A.
PA=	APPLICANT(s): Wellcome Found.
PC=, PN=	FAMILY: 20978 [AU 8820978 Austria, February 16,

SAMPLE RECORD (cont'd)

		1989
		308065 [EP 308065 European Patent Office, March 22, 1989
		596542 [EP 596542 European Patent Office, May 11, 1994
		1-068373 [JP 1068373 Japan, March 14, 1989
		3-115284 [JP 3115284 Japan, May 16, 1991
		4,957,924 [US 4957924 United States of America, September 18, 1990
		5,061,708 [US 5061708 United States of America, October 29, 1991
AN=	PRIORITY:	8719367 [GB 8719367 Great Britain, August 15, 1987
		8725939 [GB 8725939 Great Britain, November 5, 1987

/RF, RF= REFERENCES:

Blum, M.R. et al., "Single and multiple-dose pharmacokinetics of a new acyclovir prodrug, 256U87, in healthy volunteers", 31st Intersci Conf Antimicrob Agents Chemother (Sept 29-Oct 2, Chicago) 1991, Abst 763

De Miranda, P. and Burnette, T.C., "Metabolism and pharmacokinetics of the acyclovir prodrug BW 256U87 in cynomolgus monkeys", Antivir Res 1992, 17(Suppl. 1): Abst 19

Burnette, T.C. and De Miranda, P., "Metabolic disposition of BW 256U87, the L-valyl ester of acyclovir, in the rat", Antivir Res 1992, 17(Suppl. 1): Abst 142
Beauchamp, L. et al., "Amino acid esters of acyclovir as oral prodrugs", Antivir Res 1992, 17(Suppl. 1): Abst 143

(...)

"Valtrex - Wellcome's successor to Zovirax - approved", Wellcome plc News Release 1995, January 27

Wellcome plc Annual Report 1994

Prous Science Drug Data Report

SEARCH OPTIONS

BASIC INDEX

SEARCH SUFFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
—	—	All Basic Index Fields	Word	S ANTIVIRAL
/CN	CN	Chemical Name[2]	Word	S VALINE(W)2/CN
/CO	CO	Company Name[1,2]	Word	S WELLCOME/CO
/LI	LI	Licensee[2]	Word	S THERAPLIX/LI
/LO	LO	Originator[2]	Word	S WELLCOME/LO
/NA	NA	Chemical Name[2,3]	Word	S VALACV/NA
/RF	RF	Cited References[2]	Word	S ACYCLOVIR/RF
/SY	SY	Drug Name[2,4]	Word	S VALACYCLOVIR/SY
/TC	TC	Therapeutic Class Text[5]	Word	S ANTIVIRAL/TC
/TI	PI	Patent Title	Word	S NUCLEOSIDES/TI
/TN	TN	Brand Name[2]	Word	S VALTREX/TN
/TX	TX	Text	Word	S PURINE(W)NUCLEOSIDE/TX

[1] Includes Licensee (/LI, LI=) and Originator (/LO, LO=).

[2] Searchable in the Basic Index and in the Additional Indexes.

[3] Includes Chemical Name, Laboratory Code, Brand Name, and Generic Drug Name.

[4] Includes Laboratory Code,Brand Name, and Generic Drug Name.

[5] Also searchable with /DE.

ADDITIONAL INDEXES

SEARCH PREFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
AA=	AA	Prous Entry Number	Phrase	S AA=149658
AC=	AC	Application Country	Phrase	S AC=GB
AN=	PI	Patent Application/Priority Number	Phrase	S AN=GB 8719367
AU=	PI	Patent Inventor Name	Phrase	S AU=BEAUCHAMP L?
—	AZ	DIALOG Accession Number		
CN=	CN	Chemical Name[2]	Phrase	S CN=L-VALINE 2?
CO=	CO	Company Name[1,2]	Phrase	S CO=WELLCOME?
FS=	FS	File Segment	Phrase	S FS=ACTIVELY INVESTIGATED
—	IM	Image		
LI=	LI	Licensee[2]	Phrase	S LI=THERAPLIX
LO=	LO	Originator[2]	Phrase	S LO=WELLCOME
MF=	MF	Molecular Formula	Phrase	S MF=C13H20N6O4
NA=	NA	Chemical Name[2,3]	Phrase	S NA=VALACV
PA=	PI	Patent Applicant/Assignee	Word & Phrase	S PA=(WELLCOME(W)FOUND?) S PA=WELLCOME? S PA=WELLCOME?
—	PC	Preferred Compound		
PC=	PI	Patent Country	Phrase	S PC=JP
PN=	PI	Patent Number	Phrase	S PN=EP 308065
—	PP	Properties		
—	PU	Previously Published In		
RE=	RE	Related Entry Number	Phrase	S RE=151566
RF=	RF	Cited References[2]	Word	S RF=(BURNETTE(W)T(W)C)
RN=	RN	CAS(R) Registry Number	Phrase	S RN=124832-26-4
RT=	—	Record Type	Phrase	S S1 AND RT=IMAGE
ST=	ST	Development Status	Phrase	S ST=PREREGISTERED
SY=	SY	Drug Name[2,4]	Phrase	S SY=VALACYCLOVIR
TC=	TC	Therapeutic Class Code/Class Name	Phrase	S TC=71000
TN=	TN	Brand Name[2]	Phrase	S TN=VALTREX
UC=	—	Update-changed records	Phrase	S UC=9999
UD=	—	Update	Phrase	S UD=9999

SPECIAL FEATURES

For command descriptions, enter HELP LIMIT, HELP SORT, HELP RANK, HELP MAP online.

LIMIT	/**PREF** -- Compound Type -- Preferred /**SEC** -- Compound Type -- Secondary	S S2/PREF S S2/SEC
SORT	**CO, LO, NA, RN, ST, SY**	SORT S1/ALL/LO,D PRINT S5/5/1-24/LO
RANK	All phrase- and numeric-indexed fields in the Additional Indexes can be ranked.	RANK LO RANK LI S4
MAP	AN, NA, PN, PREF, PREFSEC, RN, SEC	MAP ANYY TEMP S2 MAP RN TEMP S1

PREDEFINED FORMAT OPTIONS

NO.	DIALOGWEB FORMAT	RECORD CONTENT
1	--	DIALOG Accession Number
2	--	Full Record except patents and literature references
3	Short	Full Record except text, patents and literature references
4	--	Full Record with Tagged Fields
5	Medium	Full Record except literature references
6	--	Entry Number, Compound Type and Therapeutic Class
7	--	Full Record except literature references
8	Free	Entry Number, Compound Type and Therapeutic Class
9	Long	Full Record
12	--	Full Record except patents and literature references with image.
13	--	Full Record except text, patents and literature references with image.
14	--	Full Record--tagged format with image
15	--	Full Record except literature references with image
16	--	Entry Number, Compound Type and Therapeutic Class with image
17	--	Full Record except literature references with image
18	--	Entry Number, Compound Type and Therapeutic Class with image
19	Full	Full Record with image(s)
K	--	KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats

OTHER OUTPUT OPTIONS

For an explanation, enter HELP TYPE, HELP UDF, HELP TAG online.

USER DEFINED FORMATS	Display codes listed in the Search Options tables can be used to customize output.	TYPE S3/CO, NA/1-5 PRINT S2/AN, RN/ALL
TAG	Output can be displayed with tags identifying each display field.	TYPE S3/5/1-10 TAG
DIRECT RECORD ACCESS	If the accession number of a specific record is known, it can be used to display the record directly.	TYPE 00149658/5 DISPLAY 00149658/AA,NA PRINT 00149658/9

FOR ONLINE HELP:

See HELP FIELDS 452 for searchable fields; HELP FORMAT 452 for output formats; HELP LIMIT 452 for limits; HELP RATES 452 for cost information; HELP SORT 452 for sorts.

Prous Science Drug Data Report